Sage Rhino Capital’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-85,170
| Closed | -$45.1K | – | 301 |
|
|
2025
Q1 | $45.1K | Sell |
85,170
-1
| -0% | -$2 | 0.01% | 264 |
|
|
2024
Q4 | $448K | Hold |
85,171
| – | – | 0.1% | 146 |
|
|
2024
Q3 | $1.22M | Hold |
85,171
| – | – | 0.27% | 70 |
|
|
2024
Q2 | $1.38M | Hold |
85,171
| – | – | 0.33% | 64 |
|
|
2024
Q1 | $8.62M | Hold |
85,171
| – | – | 2.03% | 12 |
|
|
2023
Q4 | $2.01M | Hold |
85,171
| – | – | 0.52% | 49 |
|
|
2023
Q3 | $1.72M | Buy |
85,171
+824
| +1% | +$16K | 0.48% | 47 |
|
|
2023
Q2 | $2.19M | Hold |
84,347
| – | – | 0.61% | 40 |
|
|
2023
Q1 | $1.75M | Hold |
84,347
| – | – | 0.51% | 46 |
|
|
2022
Q4 | $1.72M | Buy |
84,347
+1,437
| +2% | +$27.1K | 0.55% | 43 |
|
|
2022
Q3 | $2.29M | Hold |
82,910
| – | – | 0.92% | 26 |
|
|
2022
Q2 | $2.19M | Buy |
82,910
+2,000
| +2% | +$88.9K | 0.84% | 26 |
|
|
2022
Q1 | $6.47M | Hold |
80,910
| – | – | 1.96% | 13 |
|
|
2021
Q4 | $16.5M | Hold |
80,910
| – | – | 4.62% | 2 |
|
|
2021
Q3 | $26.2M | Hold |
80,910
| – | – | 7.95% | 1 |
|
|
2021
Q2 | $21M | Hold |
80,910
| – | – | 6.21% | 1 |
|
|
2021
Q1 | $31.2M | Buy |
+80,910
| New | +$32.6M | 10.26% | 1 |
|
Other funds holding VINC
Sage Rhino Capital's VINC Position: Q2 2025 in Review
Sage Rhino Capital sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 85,170 shares — an estimated $45.1K sold.
Sage Rhino Capital first reported a position in VINC in Q1 2021 and held it in 17 quarters. The position peaked at $31.2M in Q1 2021. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.
- Sage Rhino Capital reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Sage Rhino Capital sold 85,170 Vincerx Pharma, Inc. Common Stock shares in Q2 2025, an estimated $45.1K.
- Sage Rhino Capital first reported a position in Vincerx Pharma, Inc. Common Stock in Q1 2021 and held it in 17 quarters.
- Sage Rhino Capital's Vincerx Pharma, Inc. Common Stock position peaked at $31.2M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.
Based on Sage Rhino Capital's 13F filing for Q2 2025, filed 17 Jul 2025.